These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
758 related articles for article (PubMed ID: 16007682)
1. The ratio of prostate-specific antigen (PSA) to prostate volume (PSA density) as a parameter to improve the detection of prostate carcinoma in PSA values in the range of < 4 ng/mL. Stephan C; Stroebel G; Heinau M; Lenz A; Roemer A; Lein M; Schnorr D; Loening SA; Jung K Cancer; 2005 Sep; 104(5):993-1003. PubMed ID: 16007682 [TBL] [Abstract][Full Text] [Related]
2. Benign prostatic hyperplasia-associated free prostate-specific antigen improves detection of prostate cancer in an artificial neural network. Stephan C; Cammann H; Deger S; Schrader M; Meyer HA; Miller K; Lein M; Jung K Urology; 2009 Oct; 74(4):873-7. PubMed ID: 19476981 [TBL] [Abstract][Full Text] [Related]
3. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting. Guazzoni G; Nava L; Lazzeri M; Scattoni V; Lughezzani G; Maccagnano C; Dorigatti F; Ceriotti F; Pontillo M; Bini V; Freschi M; Montorsi F; Rigatti P Eur Urol; 2011 Aug; 60(2):214-22. PubMed ID: 21482022 [TBL] [Abstract][Full Text] [Related]
4. Comparative evaluation of various prostate specific antigen ratios for the early detection of prostate cancer. Ozdal OL; Aprikian AG; Bégin LR; Behlouli H; Tanguay S BJU Int; 2004 May; 93(7):970-4; discussion 974. PubMed ID: 15142145 [TBL] [Abstract][Full Text] [Related]
5. Diagnostic approach to prostate cancer using total prostate specific antigen-based parameters together. Serdar MA; Oguz O; Olgun A; Seçkin B; Ilgan S; Hasimi A; Salih M; Peker F; Kutluay T Ann Clin Lab Sci; 2002; 32(1):22-30. PubMed ID: 11848613 [TBL] [Abstract][Full Text] [Related]
6. Comparison of several combinations of free, complexed, and total PSA in the diagnosis of prostate cancer in patients with urologic symptoms. Filella X; Truan D; Alcover J; Quintó L; Molina R; Luque P; Coca F; Ballesta AM Urology; 2004 Jun; 63(6):1100-3; discussion 1103-4. PubMed ID: 15183958 [TBL] [Abstract][Full Text] [Related]
7. Clinical utility of human glandular kallikrein 2 within a neural network for prostate cancer detection. Stephan C; Jung K; Soosaipillai A; Yousef GM; Cammann H; Meyer H; Xu C; Diamandis EP BJU Int; 2005 Sep; 96(4):521-7. PubMed ID: 16104903 [TBL] [Abstract][Full Text] [Related]
8. A multicenter clinical trial on the use of alpha1-antichymotrypsin-prostate-specific antigen in prostate cancer diagnosis. Lein M; Jung K; Hammerer P; Graefen M; Semjonow A; Stieber P; Ossendorf M; Luboldt HJ; Brux B; Stephan C; Schnorr D; Loening SA Prostate; 2001 May; 47(2):77-84. PubMed ID: 11340629 [TBL] [Abstract][Full Text] [Related]
9. Percent free PSA as an additional measure in a prostate cancer screen. Miele ME Clin Lab Sci; 2001; 14(2):102-7. PubMed ID: 15625982 [TBL] [Abstract][Full Text] [Related]
10. Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial. Partin AW; Brawer MK; Bartsch G; Horninger W; Taneja SS; Lepor H; Babaian R; Childs SJ; Stamey T; Fritsche HA; Sokoll L; Chan DW; Thiel RP; Cheli CD J Urol; 2003 Nov; 170(5):1787-91. PubMed ID: 14532777 [TBL] [Abstract][Full Text] [Related]
11. Complexed prostate specific antigen density is better than the other PSA derivatives for detection of prostate cancer in men with total PSA between 2.5 and 20 ng/ml: results of a prospective multicenter study. Sözen S; Eskicorapci S; Küpeli B; Irkilata L; Altinel M; Ozer G; Uygur C; Alkibay T; Ozen H Eur Urol; 2005 Mar; 47(3):302-7. PubMed ID: 15716190 [TBL] [Abstract][Full Text] [Related]
12. [The usefulness of percentage of free prostate specific antigen/prostate specific antigen density in the diagnosis of prostate cancer]. Han G; Gao JP; Cao XL; Hong BF; Tang J Zhonghua Wai Ke Za Zhi; 2006 Mar; 44(6):379-81. PubMed ID: 16638346 [TBL] [Abstract][Full Text] [Related]
13. Complexed prostate specific antigen (PSA) reduces unnecessary prostate biopsies in the 2.6-4.0 ng/mL range of total PSA. Parsons JK; Brawer MK; Cheli CD; Partin AW; Djavan R BJU Int; 2004 Jul; 94(1):47-50. PubMed ID: 15217429 [TBL] [Abstract][Full Text] [Related]
14. Different prostate-specific antigen assays give different results on the same blood sample: an obstacle to recommending uniform limits for prostate biopsies. Stephan C; Kramer J; Meyer HA; Kristiansen G; Ziemer S; Deger S; Lein M; Loening SA; Jung K BJU Int; 2007 Jun; 99(6):1427-31. PubMed ID: 17355366 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml. Khan MA; Partin AW; Rittenhouse HG; Mikolajczyk SD; Sokoll LJ; Chan DW; Veltri RW J Urol; 2003 Sep; 170(3):723-6. PubMed ID: 12913682 [TBL] [Abstract][Full Text] [Related]
16. Ratio of alpha 1-antichymotrypsin--prostate specific antigen to total prostate specific antigen in prostate cancer diagnosis. Lein M; Jung K; Elgeti U; Brux B; Sinha P; Schnorr D; Loening SA Anticancer Res; 2000; 20(6D):4997-5001. PubMed ID: 11326657 [TBL] [Abstract][Full Text] [Related]
17. The value of percent free prostate specific antigen, prostate specific antigen density of the whole prostate and of the transition zone in Turkish men. Akduman B; Alkibay T; Tuncel A; Bozkirli I Can J Urol; 2000 Oct; 7(5):1104-9. PubMed ID: 11114873 [TBL] [Abstract][Full Text] [Related]
18. Volume-adjusted prostate-specific antigen (PSA) variables in detecting impalpable prostate cancer in men with PSA levels of 2-4 ng/mL: transabdominal measurement makes a significant contribution. Kobayashi T; Kawahara T; Nishizawa K; Ogura K; Mitsumori K; Ide Y BJU Int; 2005 Jun; 95(9):1245-8. PubMed ID: 15892809 [TBL] [Abstract][Full Text] [Related]
19. Accurate cut-off point for free to total prostate-specific antigen ratio used to improve differentiation of prostate cancer from benign prostate hyperplasia in Iranian population. Amirrasouli H; Kazerouni F; Sanadizade M; Sanadizade J; Kamalian N; Jalali M; Rahbar K; Karimi K Urol J; 2010 Jun; 7(2):99-104. PubMed ID: 20535696 [TBL] [Abstract][Full Text] [Related]
20. Value of prostate-specific antigen and prostate-specific antigen density in detection of prostate cancer in an Iranian population of men. Ghafoori M; Varedi P; Hosseini SJ; Asgari M; Shakiba M Urol J; 2009; 6(3):182-8. PubMed ID: 19711272 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]